PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To
Phase 2
Completed
- Conditions
- Sinusitis
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT00232154
- Locations
- 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
Completed
- Conditions
- Invasive Pneumococcal Disease
- Interventions
- Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2012-11-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 408
- Registration Number
- NCT00227188
- Locations
- 🇪🇸
Pfizer Investigational Site, Bilbao, Spain
Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis
Completed
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 753
- Registration Number
- NCT00227240
- Locations
- 🇩🇪
Pfizer Investigational Site, Munich, Germany
An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 78
- Registration Number
- NCT00226811
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 121
- Registration Number
- NCT00225121
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00219622
- Locations
- 🇲🇽
Pfizer Investigational Site, Monterrey, Nuevo León, Mexico
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
Phase 2
Completed
- Conditions
- Ejaculation
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 138
- Registration Number
- NCT00219635
- Locations
- 🇬🇧
Pfizer Investigational Site, Devon, United Kingdom
Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation
Phase 2
Completed
- Conditions
- Ejaculation
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 460
- Registration Number
- NCT00219583
- Locations
- 🇹🇷
Pfizer Investigational Site, Balcova, Izmir, Turkey
Assessment Of Safety Of UK-390,957
Phase 2
Completed
- Conditions
- Ejaculation
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1058
- Registration Number
- NCT00219609
- Locations
- 🇬🇧
Pfizer Investigational Site, Devon, United Kingdom
Dalacin-T Gel Post Approval Study
Phase 4
Completed
- Conditions
- Acne Vulgaris
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 134
- Registration Number
- NCT00219570
© Copyright 2025. All Rights Reserved by MedPath